SageView Advisory Group’s AtriCure ATRC Stock Holding History

SageView Advisory Group’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2	Closed	-$80	–	716
2025 Q4	$80	Buy	+2	New	+$73	﹤0.01%	2553

Other funds holding ATRC

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SageView Advisory Group's ATRC Position: Q1 2026 in Review

SageView Advisory Group sold out of AtriCure (ATRC) in Q1 2026, closing a stake of 2 shares — an estimated $80 sold.

SageView Advisory Group first reported a position in ATRC in Q4 2025 and held it in 1 quarter. The position peaked at $80 in Q4 2025. 224 funds tracked by Wall St. Rank hold ATRC as of Q1 2026.

SageView Advisory Group reported no remaining AtriCure position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 2 AtriCure shares in Q1 2026, an estimated $80.
SageView Advisory Group first reported a position in AtriCure in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's AtriCure position peaked at $80 in Q4 2025.
224 funds tracked by Wall St. Rank held AtriCure as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.